Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Free Cash Flow (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Free Cash Flow for 11 consecutive years, with -$26.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow changed N/A to -$26.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$48.6 million, a N/A change, with the full-year FY2025 number at -$71.5 million, down 129.97% from a year prior.
  • Free Cash Flow was -$26.7 million for Q4 2025 at Crescent Biopharma, down from -$16.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.1 million in Q1 2025 to a low of -$26.7 million in Q4 2025.
  • A 5-year average of -$12.4 million and a median of -$12.2 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: tumbled 302.71% in 2021, then surged 57.07% in 2023.
  • Crescent Biopharma's Free Cash Flow stood at -$12.8 million in 2021, then surged by 38.23% to -$7.9 million in 2022, then grew by 3.74% to -$7.6 million in 2023, then tumbled by 38.08% to -$10.5 million in 2024, then crashed by 153.48% to -$26.7 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Free Cash Flow are -$26.7 million (Q4 2025), -$16.8 million (Q2 2025), and -$5.1 million (Q1 2025).